IRON
Disc Medicine, Inc.Healthcare·Biotechnology
$69.57
$2.7B market cap
Revenue
$0.0M
Free Cash Flow
$-105.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
2-Year Price History
$66.82+96.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -69.4 | -69.5 | -63.5 | -62.2 | -62.2 | -0.0 | 730.2 | 31.1 | 38.5 | -128.5% | -- | -- |
| Act | 2025-Q4 | 0.0 | -59.5 | -67.0 | -60.5 | -43.3 | -43.3 | -0.0 | 791.2 | 1.9 | 35.3 | -110.6% | -67.3x | -- |
Valuation & Metrics
Market Stats
Price$69.57
Market Cap$2.7B
Enterprise Value$2.0B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-4.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-124.0M
Free Cash Flow$-105.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-119.6%
WC Change % Rev0.0%
Interest Coverage-146.0x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares5.5M
Days to Cover15.6
Change (vs Prior)+5.7%
Need at least 2 settlement dates for chart
Employees
Headcount94
Revenue / Employee$0
Gross Profit / Employee$-947
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
86.2%(+32.0% YoY)
185 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
18.1%(+7.9% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.1% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $357M | $60.24 | +$8.7M | +$151M | -0.0% | $1.89T |
| RA CAPITAL MANAGEMENT, L.P. | $157M | $57.26 | +$30.3M | +$55.8M | -4.4% | $9.44B |
| BlackRock, Inc.Passive | $145M | $52.54 | −$73K | +$11.5M | -0.2% | $5.69T |
| WELLINGTON MANAGEMENT GROUP LLP | $111M | $52.30 | +$13.9M | −$38.9M | -0.3% | $533.98B |
| STATE STREET CORPPassive | $109M | $57.08 | +$32.6M | +$49.9M | -0.2% | $2.89T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $99.1M | $58.70 | −$9.5M | +$12.2M | -0.2% | $864.93B |
| Atlas Venture Life Science Advisors, LLC | $96.8M | $21.41 | +$0 | −$55.7M | +0.3% | $790M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $87.9M | $63.94 | +$87.9M | +$87.9M | — | $4.04T |
| Frazier Life Sciences Management, L.P. | $86.6M | $46.69 | +$6.1M | −$25.6M | +2.3% | $3.89B |
| TCG Crossover Management, LLC | $85.8M | $57.20 | +$56.1M | +$56.1M | +4.6% | $3.50B |
| JPMORGAN CHASE & CO | $83.4M | $64.91 | −$13.4M | +$37.2M | -0.2% | $1.47T |
| BVF INC/IL | $81.4M | $71.84 | +$39.8M | +$81.4M | -0.3% | $3.14B |
| ORBIMED ADVISORS LLC | $68.3M | $20.84 | +$0 | −$22.2M | -8.2% | $4.38B |
| Siren, L.L.C. | $63.2M | $51.62 | +$0 | −$5.3M | +6.3% | $3.61B |
| Woodline Partners LP | $61.3M | $52.63 | +$29K | +$29.2M | -0.1% | $26.43B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $47.6M | $50.45 | +$3.8M | +$11.0M | +2.3% | $1.61T |
| Vestal Point Capital, LP | $44.8M | $67.84 | −$2.2M | +$44.8M | -0.0% | $3.58B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $42.0M | $50.63 | +$9.3M | −$8.0M | -0.8% | $7.18B |
| GOLDMAN SACHS GROUP INC | $40.9M | $64.07 | −$7.3M | +$32.6M | -0.2% | $760.93B |
| JENNISON ASSOCIATES LLC | $39.0M | $71.68 | +$5.0M | +$39.0M | +2.7% | $145.31B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.31%
avg per quarter
Holders (ex-self)
-0.36%
excl. this stock
Buyers (this Q)
+0.63%
65 buyers · $0.34B in
Sellers (this Q)
+0.03%
54 sellers · $0.27B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-4.8%
how holders react when this stock falls
On quiet Qs
+2.4%
−10% to +10% baseline
On rallies (+10%+)
-7.6%
how they react when this stock rises
Holders' portfolio flow this Q
-0.2%
outflows — trims may be forced
Sellers' portfolio flow this Q
+2.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.0%
Holder mid (any stock)
-2.8%
Holder rally (any stock)
-4.3%
Biggest decreases this quarter
First Light Asset Management, LLCexited−$41.5MPERCEPTIVE ADVISORS LLCexited−$35.8MGREAT POINT PARTNERS LLCexited−$19.9MBALYASNY ASSET MANAGEMENT LLCexited−$17.6MTimesSquare Capital Management, LLCexited−$14.9MJPMORGAN CHASE & CO−$13.4Mα-0.2First Turn Management, LLCexited−$12.2MPRICE T ROWE ASSOCIATES INC /MD/−$9.5Mα-0.2GOLDMAN SACHS GROUP INC−$7.3Mα-0.2Patient Square Capital LPexited−$5.9M
New buyers this quarter
Top-5 holders · 32.9%
FMR LLC--
RA CAPITAL MANAGEMENT, L.P.--
BlackRock, Inc.--
WELLINGTON MANAGEMENT GROUP LLP--
STATE STREET CORP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC5.6MAtlas Venture Life Science Advisors, LLC1.5MRA CAPITAL MANAGEMENT, L.P.2.5MParadigm Biocapital Advisors LP—PRICE T ROWE ASSOCIATES INC /MD/1.5MJPMORGAN CHASE & CO1.4MWELLINGTON MANAGEMENT GROUP LLP1.7MORBIMED ADVISORS LLC1.1MFrazier Life Sciences Management, L.P.1.4MBain Capital Life Sciences Investors, LLC141K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| SVRA | Savara Inc. | 4 | 141.60× |
| OLMA | Olema Pharmaceuticals, Inc. | 4 | 141.60× |
| ANNX | Annexon, Inc. | 3 | 132.75× |
| TRVI | Trevi Therapeutics, Inc. | 4 | 128.73× |
| DYN | Dyne Therapeutics, Inc. | 5 | 118.00× |
| STOK | Stoke Therapeutics, Inc. | 3 | 118.00× |
| RYTM | Rhythm Pharmaceuticals, Inc. | 5 | 110.63× |
| SION | Sionna Therapeutics, Inc. | 3 | 106.20× |
| CGON | CG Oncology, Inc. Common stock | 5 | 104.12× |
| TYRA | Tyra Biosciences, Inc. | 4 | 101.14× |
| BCAX | Bicara Therapeutics Inc. Common Stock | 3 | 96.55× |
| TNGX | Tango Therapeutics, Inc. | 4 | 94.40× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$80.001500.0%
Last Year (12 analysts)$108.335570.0%
Current Price$69.57
Analyst Ratings
1
10
Strong Buy: 1Buy: 10Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$51.13M
39 txns · 7 insiders · 653,710 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$59.87M
1 txn · 1 insider · 744,047 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | SELL | Franchi Jean M. | officer: Chief Financial Officer | 6,257 | $69.24 | $433K | $4.45M |
| 2026-04-13 | SELL | Savage William Jacob | officer: Chief Medical Officer | 5,731 | $66.38 | $380K | $5.28M |
| 2026-04-13 | SELL | Franchi Jean M. | officer: Chief Financial Officer | 400 | $69.00 | $28K | $4.87M |
| 2026-03-02 | SELL | Savage William Jacob | officer: Chief Medical Officer | 7,378 | $65.88 | $486K | $5.61M |
| 2026-02-25 | SELL | Franchi Jean M. | officer: Chief Financial Officer | 353 | $69.06 | $24K | $4.90M |
| 2026-02-18 | SELL | Franchi Jean M. | officer: Chief Financial Officer | 7,081 | $65.47 | $464K | $4.67M |
| 2026-02-17 | SELL | Savage William Jacob | officer: Chief Medical Officer | 3,256 | $62.86 | $205K | $5.82M |
| 2026-02-17 | SELL | Yu Jonathan Yen-Wen | officer: Chief Operating Officer | 3,231 | $62.86 | $203K | $3.41M |
| 2026-02-17 | SELL | Stephenson Pamela | officer: Chief Commercial Officer | 5,531 | $62.86 | $348K | $5.09M |
| 2026-02-17 | SELL | Quisel John D | director, officer: Chief Executive Officer | 13,264 | $62.86 | $834K | $14.21M |
| 2026-02-17 | SELL | Khara Rahul | officer: Chief Legal Officer | 2,853 | $62.86 | $179K | $3.28M |
| 2026-02-17 | SELL | Franchi Jean M. | officer: Chief Financial Officer | 4,075 | $62.86 | $256K | $4.93M |
| 2026-01-20 | SELL | Khara Rahul | officer: Chief Legal Officer | 1,000 | $69.74 | $70K | $2.64M |
| 2026-01-02 | SELL | Khara Rahul | officer: Chief Legal Officer | 6,500 | $78.69 | $511K | $2.97M |
| 2025-12-17 | SELL | Bitterman Kevin | director | 754 | $91.47 | $69K | $1.28M |
| 2025-12-16 | SELL | Bitterman Kevin | director | 68,923 | $91.24 | $6.29M | $1.29M |
| 2025-12-15 | SELL | Bitterman Kevin | director | 69,693 | $91.34 | $6.37M | $0 |
| 2025-12-15 | SELL | Savage William Jacob | officer: Chief Medical Officer | 13,093 | $91.22 | $1.19M | $6.91M |
| 2025-12-12 | SELL | Bitterman Kevin | director | 45,507 | $92.39 | $4.20M | $3.84M |
| 2025-12-11 | SELL | Quisel John D | director, officer: Chief Executive Officer | 40,000 | $93.05 | $3.72M | $15.99M |
Order Flow (FINRA, ~3w lag)
19.1%retail+10.9pp
29.4%dark-7.9pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
CN Healthy Food Tech Group: A Defaulting SPAC Merger Halted by Chinese Regulators
Overall Risk
9/10
Fraud
6/10
Dilution
8/10
Insolvency
9/10
Earnings Overstated
5/10
Hidden Liabilities
4/10
Legal
10/10
Audit Warnings
7/10
Hidden Upside
2/10
Contextually Acceptable
1/10